Aktuellt
SENASTE
In our view, on the basis of evidence for growing demand for Catalyst and OssDsign's strong ability to continuously add further hospital approvals, we see reasons to believe OssDsign's strong sales momentum will remain. Scalability should improve based on the closure of the Cranial PSI business line, we believe, provided sales commissions fall as a percent of sales. According to management, gross margins will rise towards 90% in 2024, which should provide support.
LÄS MER
